AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22662395 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison to a student sample
Number of subjects: 115
Study 22662395 — intervention group
Group type: COMPARATOR
Intervention: Comparison to the general population
Number of subjects: 115
Study 20937428 — intervention group
Group type: EXPERIMENTAL
Intervention: Global postural reeducation (GPR)
Number of subjects: 24
Study 20937428 — intervention group
Group type: COMPARATOR
Intervention: Static stretching exercises (SS)
Number of subjects: 24
Study 18781248 — intervention group
Group type: EXPERIMENTAL
Intervention: First-year alcohol use (abstainer, moderate drinker, heavy drinker)
Number of subjects: 952
Study 18781248 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy to abstain from alcohol at 15 months
Number of subjects: 952
Study 16105426 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy + NIPPV (Bi-level positive airway pressure mode)
Number of subjects: 36
Study 16105426 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy only
Number of subjects: 36
Study 16105426 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPPV
Number of subjects: 36
Study 12464592 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided excision
Number of subjects: 49
Study 12464592 — intervention group
Group type: COMPARATOR
Intervention: Wire-guided excision
Number of subjects: 49
Study 10069876 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (Foradil), twice daily
Number of subjects: 271
Study 10069876 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol, 4 times daily
Number of subjects: 271
Study 10069876 — intervention group
Group type: COMPARATOR
Intervention: On-demand albuterol
Number of subjects: 271
Study 8747036 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate (group II)
Number of subjects: 0
Study 8747036 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate plus HMG (group III)
Number of subjects: 0
Study 8747036 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous pregnancy (group I)
Number of subjects: 0
Study 2074867 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide suppositories
Number of subjects: 44
Study 2074867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 7005654 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste based on azulene, sodium chloride and benzalkonium chloride
Number of subjects: 0
Study 7005654 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste based on chlorhexidine
Number of subjects: 0
Study 7005654 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic detartrasis (two initial sessions)
Number of subjects: 0
Study 7005654 — intervention group
Group type: EXPERIMENTAL
Intervention: Detartrasis alone (not followed by regular oral hygiene)
Number of subjects: 0
Study 30341175 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy intervention (pharmacist visit during second or third chemotherapy infusion)
Number of subjects: 60
Study 30341175 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy intervention
Number of subjects: 60
Study 30341175 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study 29292344 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial pivot design
Number of subjects: 0
Study 29292344 — intervention group
Group type: COMPARATOR
Intervention: Single radius design
Number of subjects: 0
Study 26350034 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group receiving: 28,000 IU cholecalciferol/wk for 8 weeks before surgery, 16,000 IU/wk and 1000 mg calcium monocitrate/d after surgery, daily BMI‐adjusted protein supplementation and physical exercise
Number of subjects: 220
Study 26350034 — intervention group
Group type: COMPARATOR
Intervention: Non‐intervention group: no preoperative loading, nutritional supplementation, or obligatory physical exercise
Number of subjects: 220
Study 24674594 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated training (walking combined with cognitive exercises)
Number of subjects: 120
Study 24674594 — intervention group
Group type: COMPARATOR
Intervention: Consecutive training (walking combined with cognitive exercises)
Number of subjects: 120
Study 24674594 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated training
Number of subjects: 120
Study 24674594 — intervention group
Group type: COMPARATOR
Intervention: Consecutive training
Number of subjects: 120
Study 24674594 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated training and Consecutive training
Number of subjects: 120
Study 22917822 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol hydrochloride (1 μg/kg per minute after cardiopulmonary bypass or after distal anastomoses)
Number of subjects: 32
Study 22917822 — intervention group
Group type: COMPARATOR
Intervention: Control group (not administered landiolol hydrochloride)
Number of subjects: 32
Study 22917822 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol hydrochloride
Number of subjects: 32
Study 20430451 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate nasal drops (400 microg/day for 8 weeks)
Number of subjects: 0
Study 20430451 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS) treatment (same duration as intervention)
Number of subjects: 0
Study 17006442 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 IU Botulinum toxin A (BTX)
Number of subjects: 24
Study 17006442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 16121634 — intervention group
Group type: EXPERIMENTAL
Intervention: Karyometric measurements from biopsies of rectal mucosa
Number of subjects: 129
Study 16121634 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuclear abnormality values
Number of subjects: 129
Study 16121634 — intervention group
Group type: EXPERIMENTAL
Intervention: Tentative discriminant function (DF I,3)
Number of subjects: 129
Study 12060188 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 195
Study 12060188 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline
Number of subjects: 195
Study 10889166 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine 100 mg daily for 2 years
Number of subjects: 334
Study 10889166 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine for 1 year followed by placebo for 1 year
Number of subjects: 334
Study 10889166 — intervention group
Group type: EXPERIMENTAL
Intervention: YMDD variant HBV presence
Number of subjects: 334
Study 9364700 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined DTPa-HBV vaccine
Number of subjects: 3
Study 9364700 — intervention group
Group type: EXPERIMENTAL
Intervention: Extemporaneously mixed DTPa and HBV vaccines
Number of subjects: 3
Study 9364700 — intervention group
Group type: COMPARATOR
Intervention: Separate administration of DTPa and HBV vaccines
Number of subjects: 3
Study 1348515 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (500 micrograms)
Number of subjects: 12
Study 1348515 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (30 micrograms)
Number of subjects: 12
Study 1348515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2859305 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (15 mg)
Number of subjects: 18
Study 2859305 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam (30 mg)
Number of subjects: 18
Study 2859305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31177236 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation unit equipped with always on naturalistic lighting (IU)
Number of subjects: 90
Study 31177236 — intervention group
Group type: COMPARATOR
Intervention: Standard indoor lighting (CU)
Number of subjects: 90
Study 29388846 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose extract (400 mg/day)
Number of subjects: 120
Study 29388846 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose extract (800 mg/day)
Number of subjects: 120
Study 29388846 — intervention group
Group type: COMPARATOR
Intervention: Placebo (negative control, only dextran)
Number of subjects: 120
Study 26190177 — intervention group
Group type: EXPERIMENTAL
Intervention: R-A/L-C (anodal electrode placed over the right SMC and cathodal electrode over the left SMC)
Number of subjects: 0
Study 26190177 — intervention group
Group type: EXPERIMENTAL
Intervention: L-A/R-C (anodal electrode placed over the left SMC and cathodal electrode over the right SMC)
Number of subjects: 0
Study 26190177 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 0
Study 24742019 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl-2-cyanoacrylate (ECA)
Number of subjects: 0
Study 24742019 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment of each institution
Number of subjects: 0
Study 24742019 — intervention group
Group type: EXPERIMENTAL
Intervention: ECA
Number of subjects: 0
Study 23573201 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg CAF/kg BW)
Number of subjects: 8
Study 23573201 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee (5 mg CAF/kg BW)
Number of subjects: 8
Study 23573201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 23573201 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated coffee
Number of subjects: 8
Study 20718214 — intervention group
Group type: EXPERIMENTAL
Intervention: Cast gold partial crowns (CGPCs)
Number of subjects: 22
Study 20718214 — intervention group
Group type: COMPARATOR
Intervention: Partial ceramic crowns (PCCs)
Number of subjects: 22
Study 17499955 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-concordant clinics
Number of subjects: 256
Study 17499955 — intervention group
Group type: COMPARATOR
Intervention: Guideline-discordant clinics
Number of subjects: 256
Study 16670112 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate 40 mg kg(‐1) i.v. as a bolus before induction and 15 mg kg(‐1) h(‐1) by continuous i.v. infusion during the operation
Number of subjects: 60
Study 14563595 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose metoprolol (up to 10 mg)
Number of subjects: 21
Study 14563595 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose metoprolol (up to 20 mg)
Number of subjects: 21
Study 14563595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 11068993 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication treatment (2-week triple therapy: amoxicillin, clarithromycin, omeprazole)
Number of subjects: 50
Study 11068993 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 50
Study 8684101 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-amoxiclav (375 mg three times daily for 5 days)
Number of subjects: 300
Study 8684101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 1447587 — intervention group
Group type: EXPERIMENTAL
Intervention: Various approaches for preparing adults for cardiac catheterization
Number of subjects: 0
Study 31533391 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg/kg tranexamic acid before upper tourniquet and after closure of incision, combined with flexion position of hip (30° to 45°) and knee (60° for 70°)
Number of subjects: 90
Study 31533391 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg tranexamic acid injected before loosening tourniquet
Number of subjects: 90
Study 31533391 — intervention group
Group type: COMPARATOR
Intervention: Normal saline before loosening tourniquet
Number of subjects: 90
Study 27868259 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day workshop
Number of subjects: 112
Study 27868259 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 112
Study 25891054 — intervention group
Group type: EXPERIMENTAL
Intervention: Family‐individual‐school‐based comprehensive intervention
Number of subjects: 1446
Study 25891054 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1446
Study 22385210 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 73
Study 22385210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 21336673 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory return-to-work program
Number of subjects: 163
Study 21336673 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 163
Study 19218297 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot therapy with physiotherapy (10 sessions, more than 5000 movements)
Number of subjects: 10
Study 19218297 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot therapy with physiotherapy
Number of subjects: 10
Study 17560876 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin plus provisional glycoprotein IIb/IIIa inhibitor
Number of subjects: 6010
Study 17560876 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin plus planned glycoprotein IIb/IIIa inhibitor
Number of subjects: 6010
Study 15518172 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigerose
Number of subjects: 0
Study 11699981 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealants
Number of subjects: 9
Study 9600478 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/d
Number of subjects: 390
Study 9600478 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg/d
Number of subjects: 390
Study 9600478 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT (conjugated equine estrogen, 0.625 mg/d, and medroxyprogesterone acetate, 2.5 mg/d)
Number of subjects: 390
Study 9600478 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 390
Study 8273794 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 x/day therapy of CBS (108 mg), tetracycline HCl (500 mg), and metronidazole (250 mg)
Number of subjects: 423
Study 8273794 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 x/day therapy of CBS (108 mg), tetracycline HCl (250 mg), and metronidazole (200 mg)
Number of subjects: 423
Study 2537217 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril (0.125, 0.25, 0.5, 1, 2, 4, 8, 16, 24, 32 mg)
Number of subjects: 90
Study 2537217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 4983855 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenicillin plus gentamicin
Number of subjects: 67
Study 4983855 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin or no antibiotic
Number of subjects: 67
Study 31626835 — intervention group
Group type: EXPERIMENTAL
Intervention: Group treatment program focused on parenting skills (10 weekly sessions)
Number of subjects: 36
Study 31222797 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive disease due to lymphadenopathy (Ly)
Number of subjects: 2159
Study 31222797 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive disease due to increasing absolute lymphocyte count (ALC)
Number of subjects: 2159
Study 31222797 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive disease due to lymphadenopathy (Ly) in unfit patients
Number of subjects: 2159
Study 31222797 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive disease due to increasing absolute lymphocyte count (ALC) in unfit patients
Number of subjects: 2159
Study 25312405 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineralocorticoids
Number of subjects: 70
Study 25312405 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Number of subjects: 70
Study 25312405 — intervention group
Group type: COMPARATOR
Intervention: Vasodilators
Number of subjects: 70
Study 23627374 — intervention group
Group type: EXPERIMENTAL
Intervention: MCAT + CM (collagen matrix)
Number of subjects: 22
Study 23627374 — intervention group
Group type: COMPARATOR
Intervention: MCAT + CTG (palatal connective tissue graft)
Number of subjects: 22
Study 21301920 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone alone (MP group)
Number of subjects: 22
Study 21301920 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone in combination with azathioprine (MP + Aza group)
Number of subjects: 22
Study 19156159 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-vitamin D(3) fortified milk (400 ml per day, approximately 1000 mg of calcium and 800 IU of vitamin D(3))
Number of subjects: 140
Study 19156159 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional fortified milk)
Number of subjects: 140
Study 17474812 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated treatment (assertive outreach community treatment, family psychoeducation, social skills training)
Number of subjects: 50
Study 17474812 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 50
Study 17474812 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated treatment
Number of subjects: 50
Study 15456995 — intervention group
Group type: EXPERIMENTAL
Intervention: History of chronic bronchitis or emphysema (CB/E)
Number of subjects: 17698
Study 15456995 — intervention group
Group type: COMPARATOR
Intervention: Other lung diseases (not specified)
Number of subjects: 17698
Study 11250978 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE‐DD and AT1R‐CC genotype
Number of subjects: 885
Study 11250978 — intervention group
Group type: COMPARATOR
Intervention: Other genotype combinations
Number of subjects: 885
Study 9337498 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Couples Therapy (BCT)
Number of subjects: 80
Study 9337498 — intervention group
Group type: COMPARATOR
Intervention: Individual-Based Treatment (IBT)
Number of subjects: 80
Study 7523906 — intervention group
Group type: EXPERIMENTAL
Intervention: X-ray-induced micronuclei (MN)
Number of subjects: 0
Study 7523906 — intervention group
Group type: EXPERIMENTAL
Intervention: UV-induced unscheduled DNA synthesis (UDS)
Number of subjects: 0
Study 7523906 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous micronuclei (MN)
Number of subjects: 0
Study 7523906 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous unscheduled DNA synthesis (UDS)
Number of subjects: 0
Study 3408653 — intervention group
Group type: EXPERIMENTAL
Intervention: Philips TL‐01 lamp
Number of subjects: 10
Study 3408653 — intervention group
Group type: COMPARATOR
Intervention: Philips TL‐12 lamp
Number of subjects: 10
Study 31959171 — intervention group
Group type: EXPERIMENTAL
Intervention: Urination during flexible cystoscopy
Number of subjects: 96
Study 31959171 — intervention group
Group type: COMPARATOR
Intervention: No urination during flexible cystoscopy (Control)
Number of subjects: 96
Study 31619196 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face MBI + TAU
Number of subjects: 120
Study 31619196 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered MBI + TAU
Number of subjects: 120
Study 31619196 — intervention group
Group type: COMPARATOR
Intervention: TAU alone
Number of subjects: 120
Study 28560612 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher daily stress
Number of subjects: 276
Study 28560612 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to social support
Number of subjects: 276
Study 28560612 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare utilization (asthma-specific factor)
Number of subjects: 276
Study 25527661 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein intake ranging from 0.22 to 2.56 g · kg(‐1) · d(‐1) during early gestation.
Number of subjects: 29
Study 25527661 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein intake ranging from 0.22 to 2.56 g · kg(‐1) · d(‐1) during late gestation.
Number of subjects: 29
Study 23692953 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia patient education program with trained health professional follow-up
Number of subjects: 1206
Study 23692953 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 1206
Study 21338298 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer disclosing interviewers
Number of subjects: 0
Study 21338298 — intervention group
Group type: COMPARATOR
Intervention: Peer non-disclosing interviewers
Number of subjects: 0
Study 21338298 — intervention group
Group type: COMPARATOR
Intervention: Non-peer interviewers
Number of subjects: 0
Study 19037813 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% N-acetylcarnosine (NAC) lubricant eyedrops
Number of subjects: 50250
Study 19037813 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucyl-histidylhydrazide peptidomimetic
Number of subjects: 50250
Study 19037813 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnosine
Number of subjects: 50250
Study 19037813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50250
Study 17716321 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BoNTA) injection into frontal (10 U)
Number of subjects: 232
Study 17716321 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BoNTA) injection into temporal (6 U)
Number of subjects: 232
Study 17716321 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BoNTA) injection into glabellar (9 U)
Number of subjects: 232
Study 17716321 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BoNTA) injection into all three areas (total dose 25 U)
Number of subjects: 232
Study 17716321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study 16277296 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed discrimination task with first-order drifting luminance gratings at reference speeds of 2 and 8 deg/s, stimulus durations of 500 ms and 1000 ms
Number of subjects: 33
Study 16277296 — intervention group
Group type: COMPARATOR
Intervention: Older age group (mean age 71 years)
Number of subjects: 33
Study 16277296 — intervention group
Group type: COMPARATOR
Intervention: Older women in the older age group
Number of subjects: 33
Study 12015496 — intervention group
Group type: EXPERIMENTAL
Intervention: Early feeding regimen (group B) - clear fluids on the first postoperative day, regular diet after tolerating 500 mL of clear fluids.
Number of subjects: 96
Study 12015496 — intervention group
Group type: COMPARATOR
Intervention: Traditional feeding group (group A) - nothing by mouth until bowel function documented, then advanced slowly to solid diet.
Number of subjects: 96
Study 12015496 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 96
Study 10468076 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (140 microg/kg/min x 6 minutes)
Number of subjects: 32